Browse this page
CyberKnife®, also known as stereotactic body radiation therapy (SBRT), is non-surgical, highly precise, targeted radiation, with minimal damage to surrounding healthy tissue.
Prostate cancer treatment
Unlike conventional prostate radiation therapy that can take up to 40 sessions, CyberKnife treats prostate cancer in only five treatments. This treatment is extremely accurate and painless. This treatment causes minimal side effects and requires virtually no recovery time.
What does this mean for you? You can get back to your normal life almost immediately. With CyberKnife, get treated for prostate cancer while maintaining your regular lifestyle.
In addition, it can be used in conjunction with conventional radiation for men with high-risk prostate cancer.
How does CyberKnife treat prostate cancer?
This therapy uses a combination of robotics, image guidance systems and computers to deliver highly concentrated doses of radiation to the prostate while protecting surrounding healthy tissue. The machine that adjusts for patient or tumor movement during treatment (intrafraction motion), making it especially suitable for the prostate and convenient for you.
CyberKnife can treat tumors anywhere in the body.
Including the lung, breast, brain/spine, head/neck, and GI tract. CyberKnife can treat inoperable tumors or those tumors that may be in hard to reach places. Because this method of treatment is painless, precise, and has minimal side-effects, it can be a great alternative to surgery.
Why choose MedStar Georgetown University Hospital?
MedStar Georgetown University Hospital was the first hospital on the East Coast to offer the CyberKnife technology. Our team is among the world’s most experienced CyberKnife sites having treated more than 2,000 patients with prostate cancer and performed more than 30,000 treatments in total. Count on our board-certified specialists to provide the comprehensive and personalized care necessary to determine the best treatment for your needs.
Through our research engine, Georgetown Lombardi Comprehensive Cancer Center, the only National Cancer Institute (NCI)-designated comprehensive cancer center in the Washington, D.C., region, we offer access to the clinical trials and the latest breakthrough in cancer care.
Ask a doctor videos
CyberKnife for prostate cancer: Ask Dr. Sean Collins
Radiation Oncologist Sean Collins, MD, PhD, is director of the CyberKnife Prostate Program at MedStar Georgetown University Hospital. In this video, Dr. Collins answers commonly asked questions about CyberKnife for prostate cancer.
Facebook live: CyberKnife for prostate cancer
We were LIVE with Dr. Sean Collins, director of the CyberKnife® Prostate Program, and his patient discussing how CyberKnife is used to treat prostate cancer in just 5 sessions.
How does CyberKnife work?
The non-surgical CyberKnife® Robotic Radiosurgery System destroys tumors using highly precise, targeted radiation, with minimal damage to surrounding healthy tissue. Unlike conventional prostate radiation therapy that can take up to 40 sessions, CyberKnife, also known as stereotactic body radiation therapy (SBRT), is complete after only five treatments.
CyberKnife uses a combination of robotics, image guidance systems and computers to deliver highly concentrated doses of radiation to the prostate while protecting surrounding healthy tissue. CyberKnife is the only stereotactic robotic radiosurgery system on the market that adjusts for patient or tumor movement during treatment (intrafraction motion), making it especially suitable for the prostate and convenient for you.
- CyberKnife treatment begins with the implantation in the prostate of four tiny gold fiducials that act as markers or targets for the system’s missile-like rays.
- Afterward, a team of experienced physicians uses MRIs, CT scans and three-dimensional technology to pinpoint the location of your cancer and adjacent critical structures to create a treatment plan.
- A week or two later, you will return for five days of therapy over one to two weeks, with each treatment lasting about 30 minutes.
- You are usually able to resume your normal activities almost immediately.
- Follow-up consists of regularly scheduled PSA (prostate-specific antigen) tests and monitoring.
What are the benefits of CyberKnife treatment for prostate cancer?
Not only can CyberKnife target tumors that were previously considered unreachable or inoperable, the sophisticated system is a great advancement in patient ease and comfort, offering the following advantages:
- Minimal pain: Because the procedure is a nonsurgical approach, there is no anesthesia, incision, blood loss or recovery time.
- Only five treatments: Not the 40 needed with other forms of radiation therapy.
- No overnight hospitalization: An outpatient treatment, CyberKnife usually allows you to return home the same day.
- Faster and more accurate: Approaching its target from more than 1,400 angles, CyberKnife can deliver high doses of radiation to tumors while avoiding surrounding, healthy tissue.
- Quick recovery times: Get back to your normal life almost immediately, unlike the two-to-four-week recovery period that can be expected following traditional prostate surgery, such as prostatectomy (prostate removal).
Does CyberKnife treatment result in positive outcomes?
Recent research has proven that higher doses of radiation decrease the chance of prostate cancer recurring. CyberKnife’s laser-like accuracy can deliver those highly concentrated doses while avoiding nearby healthy tissue, including such critical structures as the bladder and rectum leading to fewer side effects.
Other studies—including national, multi-institutional protocols, many conducted at MedStar Health—indicate that CyberKnife is as effective as other radiation therapies for treating low-and intermediate-risk prostate cancer patients. Another study shows that CyberKnife produces quality-of-life outcomes equivalent to or better than IMRT or seed therapy. As an added benefit, CyberKnife treatment is completed within only five visits.
Location: Change location Enter your location
Peter Hyung-Kyun Ahn, MD
Sean Philip Collins, MD,PhD
Nitika Paudel, MD
Sonali Rudra, MD
Andrew Satinsky, MD
Keith R. Unger, MD